NCT07490522 The Remote Monitoring of Gout Feasibility Study in Primary Care
| NCT ID | NCT07490522 |
| Status | Recruiting |
| Phase | — |
| Sponsor | Diakonhjemmet Hospital |
| Condition | Gout |
| Study Type | INTERVENTIONAL |
| Enrollment | 50 participants |
| Start Date | 2026-04 |
| Primary Completion | 2027-12 |
Eligibility & Interventions
Eligibility Fast-Check
Enter your details for a quick preliminary check. This does not replace medical advice.
What to Expect as a Participant
You will actively receive the study intervention — which may be a drug, biologic, device, or procedure.
This trial targets 50 participants in total. It began in 2026-04 with a primary completion date of 2027-12.
⚠ This information is for research awareness only. Always consult your physician before joining any clinical trial. Participation is voluntary and you may withdraw at any time.
Brief Summary
The goal of this feasibility study is to determine the feasibility of a patient self-management app (MinUrinsyregikt) for patients with gout. The primary objectives of the study are: 1. To determine the feasibility of a patient self-management app for patients with gout receiving GP follow-up. 2. To determine the feasibility of conducting a future randomised controlled trial to test the effectiveness of the app for patients with gout in primary care. Participants will be asked to test the self-management app for 3 months. Data will be collected from the participants and their GPs.
Eligibility Criteria
Patients are eligible to be included in the study only if all the following criteria apply: * Adults ≥18 years of age at screening * Patients with a clinical diagnosis of gout * Serum urate level \>360 µmol/L at inclusion * Indication for urate lowering therapy assessed by medical doctor * Having a smartphone/tablet Patients are excluded from the study if any of the following criteria apply: * Pregnant or breastfeeding * Contraindication for urate lowering therapy * Does not understand Norwegian language * Major co-morbidities (e.g., malignancies, severe chronic kidney disease, severe mental disorders)
Contact & Investigator
Fiona Aanesen
PRINCIPAL INVESTIGATOR
Diakonhjemmet Hospital
Frequently Asked Questions
Who can join the NCT07490522 clinical trial?
This trial is open to participants of all sexes, aged 18 Years or older, studying Gout. Full inclusion and exclusion criteria are listed in the Eligibility Criteria section. Always confirm your eligibility with the research team before applying.
Is NCT07490522 currently recruiting?
Yes, NCT07490522 is actively recruiting participants. Contact the research team at fiona.aanesen@diakonsyk.no for enrollment information.
Where is the NCT07490522 trial being conducted?
This trial is being conducted at Oslo, Norway.
Who is sponsoring the NCT07490522 clinical trial?
NCT07490522 is sponsored by Diakonhjemmet Hospital. The principal investigator is Fiona Aanesen at Diakonhjemmet Hospital. The trial plans to enroll 50 participants.